Categories
Change Password!
Reset Password!
GLP-1 RAs emerge as an effective strategy for reducing cardiovascular risk in older adults with type 2 diabetes, despite an increased incidence of gastrointestinal adverse events.
As populations age and the cardiovascular (CV) burden of type 2 diabetes continues to escalate, the demand for therapies that extend protection beyond glycemic control remains increasingly urgent. In response to this clinical challenge, the investigators examined whether glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could improve CV outcomes while preserving an acceptable safety profile.
In this systematic review and meta-analysis, a comprehensive review of major scientific literature repositories was undertaken to identify randomized controlled trials (RCTs) involving older adults with type 2 diabetes that assessed GLP-1 RAs against placebo or alternative therapies. The analysis centered on CV outcomes while simultaneously examining clinically relevant safety events, including gastrointestinal intolerance and hypoglycemia. Comparative risks were then pooled within a random-effects framework and expressed as risk ratios with accompanying 95% confidence intervals.
The final evidence base comprised six RCTs reported across five publications and included 8,889 older adults with a mean age of 71.8 years.
The review highlighted a favorable balance between CV efficacy and overall safety for GLP-1 RAs in elderly patients with type 2 diabetes, supporting their growing relevance in age-specific diabetes care.
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Cardiovascular Outcomes and Safety of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
Weifei Gao et al.
Comments (0)